PKP2 heart condition natural history study
Part of Genetic & congenital, Heart & circulation clinical trials.
This study is for people with a specific genetic heart condition (PKP2-related arrhythmogenic cardiomyopathy) who already have an ICD. It does not test a new treatment but instead follows participants over time to learn more about the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have been diagnosed with arrhythmogenic cardiomyopathy (a heart condition that affects the heart muscle and rhythm).
- You have a confirmed disease-causing change (mutation) in the PKP2 gene from a certified genetic test.
- You have had an implantable cardioverter-defibrillator (ICD) for at least 6 months.
- Your heart's pumping strength (left ventricular ejection fraction) is 50% or higher, as measured in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies children with inherited (genetic) heart conditions that started before age 16. It may help improve how doctors identify the genetic cause and understand which families are affected.
This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
This Phase 1 trial tests RP-A601 (a gene-delivery type treatment) to see if it can reduce dangerous heart rhythm problems in people with PKP2-related arrhythmogenic cardiomyopathy (ACM). Because it’s an early safety/dose study, the main goal is to check safety and how the body responds.
This study follows participants who have already received the gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. It tracks their long-term safety and health outcomes, with no new treatment given.
This study uses a special whole-heart scan (PET combined with MRI) to better understand the tissue and metabolism patterns in people with arrhythmogenic cardiomyopathy. The goal is to see whether these scan patterns relate to symptoms now and how the disease may change over time.
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.